Stockreport

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics, Inc.  (DSGN) 
PDF Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in [Read more]